8,721 Shares in BioNTech SE (NASDAQ:BNTX) Bought by Bellevue Group AG

Bellevue Group AG purchased a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 8,721 shares of the company's stock, valued at approximately $1,036,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BNTX. CANADA LIFE ASSURANCE Co lifted its stake in BioNTech by 79.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 3,426 shares of the company's stock valued at $316,000 after buying an additional 1,518 shares during the period. Tidal Investments LLC bought a new position in BioNTech during the 1st quarter worth approximately $703,000. EverSource Wealth Advisors LLC boosted its stake in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock worth $43,000 after acquiring an additional 252 shares during the last quarter. GAMMA Investing LLC grew its holdings in BioNTech by 86.9% during the second quarter. GAMMA Investing LLC now owns 512 shares of the company's stock valued at $41,000 after purchasing an additional 238 shares during the period. Finally, Granite Bay Wealth Management LLC bought a new stake in BioNTech in the second quarter valued at approximately $1,483,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft increased their price target on BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a report on Thursday, September 19th. Morgan Stanley raised BioNTech from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. TD Cowen cut their price target on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a research note on Tuesday, November 5th. Evercore ISI raised shares of BioNTech from an "in-line" rating to an "outperform" rating and increased their price objective for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. Finally, HSBC boosted their price objective on shares of BioNTech from $97.00 to $136.00 and gave the company a "buy" rating in a research report on Monday, October 7th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $138.67.

BioNTech Stock Down 1.9 %

BNTX traded down $2.33 during trading hours on Friday, hitting $118.39. The stock had a trading volume of 518,891 shares, compared to its average volume of 1,137,633. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The company's fifty day simple moving average is $113.81 and its 200 day simple moving average is $98.68. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business's revenue for the quarter was up 38.9% on a year-over-year basis. During the same period last year, the company earned $0.73 earnings per share. Analysts predict that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.